SCHEDULE: First Light Asset Management Discloses NeoGenomics Stake

First Light Asset Management, LLC and its principal, Mathew P. Arens, disclosed significant beneficial ownership in Neogenomics, Inc., holding 7.57% of common stock.

Summary

• First Light Asset Management, LLC and Mathew P. Arens jointly filed a Schedule 13G, reporting beneficial ownership in Neogenomics, Inc. common stock.
• First Light Asset Management, LLC beneficially owns 9,544,749 shares, representing 7.39% of the class.
• Mathew P. Arens beneficially owns a total of 9,784,749 shares, representing 7.57% of the class.
• Mr. Arens's ownership includes shares managed by First Light Asset Management, LLC, 100,000 shares held individually with sole control, and 140,000 shares held in a joint account with shared control.
• The shares were acquired in the ordinary course of business and not for the purpose of changing or influencing control of Neogenomics, Inc.

Sentiment

Score: 5

Explanation: Neutral, as this is a standard beneficial ownership disclosure and does not contain performance or strategic updates.

Positives

• The disclosure of a significant institutional stake by First Light Asset Management and Mathew P. Arens may be viewed by some investors as a vote of confidence in Neogenomics, Inc.

Future Outlook

No forward-looking statements or guidance are provided in this beneficial ownership disclosure.

Management Comments

• Kurt T. Peterson, Chief Compliance Officer of First Light Asset Management, LLC, and Mathew P. Arens, Chief Executive Officer of First Light Asset Management, LLC, certified that the securities were acquired and are held in the ordinary course of business and not for the purpose or with the effect of changing or influencing the control of the issuer.

Industry Context

This filing indicates a significant institutional investment in a company operating within the healthcare diagnostics sector. It does not provide broader industry trends or competitive analysis.

Stakeholder Impact

• Primarily impacts shareholders by disclosing a significant institutional holder, which can influence market perception of the company's ownership structure.

Key Dates

Keywords

Neogenomics, NEO, First Light Asset Management, Mathew P. Arens, Schedule 13G, beneficial ownership, common stock, investment, healthcare diagnostics